Janux Therapeutics, Inc.
JANX
$13.79
-$0.26-1.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.39% | 28.19% | -44.03% | -16.28% | 27.95% |
| Total Depreciation and Amortization | -6.59% | -7.39% | 4.24% | 1.37% | 0.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.51% | -23.17% | -11.22% | 94.98% | -73.38% |
| Change in Net Operating Assets | -146.75% | 74.27% | 826.74% | -49.57% | -102.69% |
| Cash from Operations | -122.01% | 46.01% | -39.88% | -1.79% | -649.66% |
| Capital Expenditure | -13.98% | 80.34% | -27.49% | -783.33% | -68.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 253.01% | 312.73% | 100.60% | -1,101.00% | 167.49% |
| Cash from Investing | 255.68% | 431.75% | 100.46% | -1,103.34% | 167.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 497.16% | -48.32% | 5.88% | -99.77% | 23,347.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 497.16% | -48.32% | 72.20% | -99.86% | 23,347.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 197.24% | 80.95% | 94.03% | -188.36% | 3,239.82% |